The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies (RECIPE)

The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial

To evaluate the efficacy and safety of rituximab (genetical recombination) intravenously administered to CIDP patients with positive or negative IgG4 autoantibody.

Study Overview

• Status: Completed
• Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
• Intervention / Treatment: Biological: Rituximab (genetical recombination); Other: Placebo

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Phase 2

Contacts and Locations

Study Locations

• Japan
  • Chiba, Japan
    • Chiba University Hospital
  • Fukuoka, Japan
    • Kyushu University Hospital
  • Ube, Japan
    • Yamaguchi University Hospital
  • Aich
    • Nagoya, Aich, Japan, 466-8560
      • Nagoya University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients with definite CIDP diagnosed according to the modified diagnostic criteria of European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) (2010) by the time of enrollment in the study

2. Patients meeting one of the following conditions:

   (i) Patients with positive serum IgG4 autoantibody (CNTN-1 or NF-155) confirmed by the time of enrollment in the study

   (ii) Patients with negative serum IgG4 autoantibody (CNTN-1 and NF-155) confirmed by the time of enrollment in the study

3. Patients with refractory CIDP not responding adequately to treatment with corticosteroid for 12 weeks, and intravenous immunoglobulin therapy (IVIg) for 8 weeks by the time of enrollment in the study, or those who are unable to administer or continue corticosteroid and IVIg
4. Patients with total adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale scores of 2 to 8 at both preliminary enrollment and enrollment, and with the total score at enrollment equal to or worse than that at preliminary enrollment
5. Patients aged 12 years or older at informed consent
6. Patients who give their voluntary written consent after having received adequate information on this study (legally acceptable representatives should also give consent for underage patients, and informed assent should be obtained from children aged 12 to 15)

Exclusion Criteria:

1. Patients with disease meeting one of the following exclusion criteria defined in the modified EFNS/PNS diagnostic criteria (2010).

   (i) Borrelia burgdorferi infection (Lyme disease), diphtheria, drug or toxin exposure probably to have caused the neuropathy Hereditary demyelinating neuropathy

   (ii) Prominent sphincter disturbance

   (iii) Diagnosis of multifocal motor neuropathy

   (iv) IgM monoclonal gammopathy with high titre antibodies to myelin-associated glycoprotein

   (v) Other causes for a demyelinating neuropathy including POEMS syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexus neuropathy PNS lymphoma and amyloidosis may occasionally have demyelinating features

2. Patients who have started or have increased the dose of corticosteroid for CIDP within 12 weeks prior to the enrollment
3. Patients who have started or have increased the dose of IVIg within 8 weeks prior to the enrollment
4. Patients who have underwent plasmapheresis within 8 weeks prior to the enrollment or patients with refractory disease not responding adequately to 8 weeks of plasmapheresis (plasma exchange or double-filtration plasmapheresis)
5. Patients who have started or have increased the dose of an immunosuppressant (azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, interferon alpha, interferon beta, etanercept, methotrexate, mitoxantrone, alemtuzumab, cladribine, tacrolimus, fingolimod) within 12 weeks prior to the enrollment
6. Patients who have underwent hematopoietic stem cell transplant prior to the enrollment
7. Patients who have used rituximab (genetical recombination) prior to the enrollment
8. Patients who have participated in another clinical study within 3 months prior to the enrollment (enrollment is allowed for those participating in a clinical study in the range of Indications or Dosage and Administration in Japan) or patients who are participating in another study
9. Patients with poorly controlled diabetes (HbA1c of 7 % or higher)
10. Patients who have or are suspected to have active infection (infection requiring treatment with systemic antimicrobial, antifungal, or antiviral agents) at the time of the enrollment
11. Patients tested positive for HBs antigen, HBs antibody, HBc antibody, and/or HCV antibody (patients with positive HBs antibody or HBc antibody can be enrolled when a hepatitis B virus-DNA test is negative [below the limit of detection], and hepatitis B virus-DNA and aspartate/alanine transaminase levels are monitored at fixed intervals), or patients with positive HIV antibody or HTLV-1 antibody at the time of the enrollment
12. Patients with leukopenia (less than 2,000 /mm3), neutropenia (less than 1,000 /mm3), or lymphopenia (less than 500 /mm3) at the time of the enrollment
13. Patients with history of serious hypersensitivity or anaphylactic reaction to one of the ingredients in the investigational drug or murine protein-containing products
14. Patients with serious comorbidity (e.g., hepatic, renal, cardiac, lung, hematologic, or brain disease)
15. Female patients who are pregnant, lactating, or potentially pregnant, or patients who are not willing to use contraceptive measures during the study period
16. Patients who are judged to be unsuitable by the investigator or a sub-investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Rituximab group (IgG4 autoantibody positive)	Biological: Rituximab (genetical recombination); Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
Placebo Comparator: Placebo group (IgG4 autoantibody positive)	Other: Placebo; Administer placebo IV infusion once weekly for 4 doses.
Active Comparator: Rituximab group (IgG4 autoantibody negative)	Biological: Rituximab (genetical recombination); Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of patients with improvement in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale	Primary analysis will compare scores of adjusted INCAT Disability Scale evaluated prior to treatment (at the time of enrollment) and scores at each timepoint after week 26 to calculate the proportion of patients who achieve an improvement of one and more from the baseline. The INCAT Disability Scale is an index to evaluate disorders in lower (gait) and upper (elevation of the upper arms and fine movement of the fingertips) extremities. The INCAT score is a 10-point scale and ranges from 0 (normal) to 10 (worst). For the "adjusted" INCAT score, a change in upper extremity score from 0 to 1 or 1 to 0 will not be considered meaningful in this evaluation.	Up to 52 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in grip strength (kPa)	The differences of Grip strength (kPa) between prior to treatment and at each timepoint are summarized.	Up to 52 weeks
Change in Rasch-built Overall Disability Scale (R-ODS) score	The differences of R-ODS score between prior to treatment and at each timepoint are summarized. R-ODS is consist of a 24-item questionnaire about daily living task with 3 response options: (0) "impossible to perform," (1) "performed with difficulty," and (2) "easily performed. The R-ODS score is a 48-point scale (range: 0-48), and is converted into a centile metric score with values ranging from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).	Up to 52 weeks
Change in Medical Research Council (MRC) Sum Score	The differences of MRC Sum Score between prior to treatment and at each timepoint are summarized. The MRC Sum Score is a scale to assess for 8 muscle groups (right and left side) as follow: Shoulder abduction, Elbow flexion, Wrist extension, Index finger abduction, Hip flexion, Knee extension, Foot dorsiflexion, Great toe dorsiflexion.The MRC Sum Score is a 80-point scale and ranges from 0 (paralysis) to 80 (normal strength).	Up to 52 weeks
Change in motor nerve distal latency	The differences of distal latency between prior to treatment and at each timepoint are summarized.	Up to 52 weeks
Change in motor nerve proximal latency	The differences of proximal latency between prior to treatment and at each timepoint are summarized.	Up to 52 weeks
Change in motor nerve compound muscle action potential (CMAP)	The differences of CMAP between prior to treatment and at each timepoint are summarized.	Up to 52 weeks
Change in motor nerve conduction velocity	The differences of motor nerve conduction velocity between prior to treatment and at each timepoint are summarized.	Up to 52 weeks
Cerebrospinal fluid protein level	Cerebrospinal fluid protein level at each timepoint are summarized.	Up to 52 weeks
B cell counts (CD19 positive and CD20 positive cell counts) and T cell counts (CD3 positive, CD4 positive, and CD8 positive cell counts)	B cell counts (CD19 positive and CD20 positive cell counts) and T cell counts (CD3 positive, CD4 positive, and CD8 positive cell counts) at each timepoint are summarized.	Up to 52 weeks
Expression of HACA	The number of patients expressing HACA, and the proportion and its 95% confidence interval of these patients at each timepoint are summarized.	Up to 52 weeks
Serum rituximab (genetical recombination) level	Serum rituximab (genetical recombination) level at each timepoint are summarized.	Up to 52 weeks
Maximum serum concentration (Cmax) of rituximab (genetical recombination)	Cmax of rituximab (genetical recombination) is summarized.	Up to 52 weeks
Area under the curve (AUC) of blood concentration of rituximab (genetical recombination)	AUC of blood concentration of rituximab (genetical recombination) is summarized.	Up to 52 weeks
Half-life (t1/2) of rituximab (genetical recombination)	t1/2 of rituximab (genetical recombination) is summarized.	Up to 52 weeks
Clearance (CL) of rituximab (genetical recombination)	CL of rituximab (genetical recombination) is summarized.	Up to 52 weeks
Mean residence time (MRT) of rituximab (genetical recombination)	MRT of rituximab (genetical recombination) is summarized.	Up to 52 weeks
Volume of distribution (Vds) of rituximab (genetical recombination) level	Vds of rituximab (genetical recombination) is summarized.	Up to 52 weeks
Serum antibody titers of IgG4 (CNTN-1 and NF-155) and these IgG subclass	Serum titers (CNTN-1 and NF-155, and these IgG subclasses 1 to 4) at each timepoint are summarized.	Up to 52 weeks
Serum neurofilament	Serum neurofilament level at each timepoint is summarized.	Up to 52 weeks

Collaborators and Investigators

• Sponsor: Nagoya University
• Collaborators: Japan Agency for Medical Research and Development; Zenyaku Kogyo Co., Ltd.
• Investigators: Principal Investigator: Masahiro Iijima, Ph. D, Nagoya University Hospital

Publications and helpful links

General Publications

• Shimizu S, Iijima M, Fukami Y, Tamura N, Nakatochi M, Ando M, Nishi R, Koike H, Kaida K, Koga M, Kanda T, Ogata H, Kira JI, Mori M, Kuwabara S, Katsuno M. Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Res Protoc. 2020 Apr 1;9(4):e17117. doi: 10.2196/17117.

Study record dates

Study Major Dates

• Study Start (Actual): March 28, 2019
• Primary Completion (Actual): May 27, 2021
• Study Completion (Actual): May 27, 2021

Study Registration Dates

• First Submitted: February 19, 2019
• First Submitted That Met QC Criteria: March 3, 2019
• First Posted (Actual): March 6, 2019

Study Record Updates

• Last Update Posted (Actual): August 20, 2021
• Last Update Submitted That Met QC Criteria: August 19, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Keywords: Rituximab; IgG4 autoantibody; Neurofascin-155; Contactin-1
• Additional Relevant MeSH Terms: Nervous System Diseases; Immune System Diseases; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Neuromuscular Diseases; Peripheral Nervous System Diseases; Polyneuropathies; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Rituximab
• Other Study ID Numbers: CAMCR-011; jRCT2041180037 (Registry Identifier: Japan Registry of Clinical Tials); UMIN000035753 (Registry Identifier: UMIN Clinical Trials Registry)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No